CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population

被引:21
|
作者
Dorado, Pedro [2 ]
Heras, Natalia [3 ]
Machin, Esther [2 ]
Hernandez, Francisco [4 ]
Teran, Enrique [1 ,3 ]
LLerena, Adrian [2 ,5 ]
机构
[1] Univ San Francisco Quito, Coll Hlth Sci, Quito, Ecuador
[2] Extremadura Univ Hosp & Med Sch, CICAB Clin Res Ctr, Badajoz, Spain
[3] Cent Univ Ecuador, Biomed Ctr, Quito, Ecuador
[4] Univ Estatal Guayaquil, Sch Med, Guayaquil, Ecuador
[5] Univ Extremadura, Hosp Univ Infanta Cristina, SES, E-06080 Badajoz, Spain
关键词
CYP2D6; Dextromethorphan; Ecuador; Pharmacogenetics; GENETIC POLYMORPHISMS; MEXICAN-AMERICANS; AMERINDIANS; METABOLISM; PHARMACOGENETICS; DEBRISOQUINE; DIVERSITY; MESTIZOS; CAPACITY; PANAMA;
D O I
10.1007/s00228-011-1147-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabolic ratio (MR), which is a marker of CYP2D6 activity, were studied in 118 unrelated healthy Ecuadorians. Genotyping of CYP2D6 was performed by amplification of entire CYP2D6 gene by XL-PCR for CYP2D6*5 and multiplication alleles and by real time-PCR for CYP2D6 *2, *3, *4, *6, *10, *17, *29, *35, *41, and copy number. The plasma levels of DXM and its metabolite DXT were determined on a high-performance liquid chromatography-UV system. The proportions of non-functional alleles were 0.4, 10.6, 0.8, 2.1, and 0% for CYP2D6*3, *4, *4 x N, *5, and *6, respectively. Genotypically, only one of the subjects (0.9%) was homozygous for two inactive alleles and phenotypically classified as a poor metabolizer (PM). The MRs (mean +/- standard deviation) corresponding to "activity scores" of 0, 0.5, 1, 1.5, 2, and 2.5 were 10.57 (n = 1), 1.63 +/- 0.35 (n = 2), 1.16 +/- 0.74 (n = 29), 1.00 +/- 0.47 (n = 8), 1.24 +/- 0.82 (n = 76), and 1.30 +/- 0.32 (n = 2), respectively. Our data suggest that only 1% of subjects of this Ecuadorian population were PMs and that none were phenotypically ultrarapid metabolizers, which is in agreement with previous findings in other Amerindian populations.
引用
收藏
页码:637 / 644
页数:8
相关论文
共 50 条
  • [1] CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
    Pedro Dorado
    Natalia Heras
    Esther Machín
    Francisco Hernández
    Enrique Teran
    Adrián LLerena
    European Journal of Clinical Pharmacology, 2012, 68 : 637 - 644
  • [2] CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
    LLerena, A.
    Dorado, P.
    Ramirez, R.
    Gonzalez, I.
    Alvarez, M.
    Penas-LLedo, E. M.
    Perez, B.
    Calzadilla, L. R.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (02): : 176 - 183
  • [3] CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
    A LLerena
    P Dorado
    R Ramírez
    I González
    M Álvarez
    E M Peñas-LLedó
    B Pérez
    L R Calzadilla
    The Pharmacogenomics Journal, 2012, 12 : 176 - 183
  • [4] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [5] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [6] CYP2D6 genotype and phenotype determination in a Mexican Mestizo population
    López, M
    Guerrero, J
    Jung-Cook, H
    Alonso, ME
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (10) : 749 - 754
  • [7] CYP2D6 phenotype and genotype in a Canadian Native Indian population
    Nowak, MP
    Tyndale, RF
    Sellers, EM
    PHARMACOGENETICS, 1997, 7 (02): : 145 - 148
  • [8] CYP2D6 genotype and phenotype determination in a Mexican Mestizo population
    Marisol López
    Jorge Guerrero
    Helgi Jung–Cook
    María Elisa Alonso
    European Journal of Clinical Pharmacology, 2005, 61 : 749 - 754
  • [9] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [10] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651